Precigen

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the following segments: Biopharmaceuticals, Exemplar, and Trans Ova. The Biopharmaceuticals segment is involved in advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. It also engages in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The Exemplar segment is focused on developing research models and services for healthcare research applications. The Trans Ova segment provides bovine reproductive technologies. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Precigen (PGEN) reports strong Q1 performance and growth opportunities

Precigen's Q1 2023 earnings call highlighted financial strength, progress in innovative therapies, and a focus on cost-effective drug development.
The company's platforms like PRGM 2012 and UltraCAR show promise in treating challenging diseases, supported by a solid cash runway into late 2024.
While facing challenges in program transparency and target rights, Precigen's opportunities lie in rapid commercialization, personalized medicine, and market expansion.

Precigen (PGEN) reports strong Q2 performance and FDA alignment

Precigen (PGEN) shows promising performance with positive Phase I data for PRGN-2012 and cost-saving measures implemented.
Strengths lie in FDA confirmation, positive regulatory developments, and extended cash runway to 2025.
Challenges include safety follow-up, commercial readiness, and balancing program focus amidst cost-saving measures.
Opportunities arise from international licensure discussions, repeat dosing scenarios, and FDA alignment for accelerated approval.

Precigen (PGEN) projects strong growth in 2024 with key milestones

Precigen (PGEN) anticipates a significant year ahead with key milestones for PRGN-2012 and UltraCAR-T therapies.
Financially, the company aims to balance R&D investments with cost reductions to support strategic initiatives.
Analysts' inquiries and the focus on strengthening the balance sheet underscore the company's commitment to sustainable growth.

Precigen (PGEN) excels with PRGN-2012 gene therapy, poised for growth

Precigen (PGEN) showcased strong performance with PRGN-2012, supported by positive clinical trial outcomes and regulatory milestones.
While challenges like trial enrollment pace and market strategies exist, strategic initiatives and financial updates indicate a proactive approach to addressing them.
The company's focus on commercialization and workforce optimization presents opportunities for growth and market leadership in the gene therapy sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

–  HPV is responsible for more than 90 percent of cervical cancer cases globally with approximately 300,000 women living with cervical cancer in the US – –  Current response rates to second line treatments in recurrent or metastatic cervical cancer are very low and associated with a high rate of toxicity  – – PRGN-2009 is designed to generate de novo T-cell immune response against HPV 16/18-positive solid tumors cells and is differentiated from other platforms due to the ability of gorilla adenovectors to enable repeat administrations – –  PRGN-2009 Phase 1 data to be presented at the 2023 ASCO annual meeting on June 3 (Abstract # 2628); PRGN-2009 in combination with a checkpoint inhibitor demonstrated a favorable safety profile and resulted in a 30% ORR in patients with heavily pre-treated HPV-associated cancers, including those who have previously failed checkpoint inhibitors – –  Phase 2 study of PRGN-2009 is in combination with pembrolizumab in the second line setting in patients with recurrent or metastatic cervical cancer previously treated with pembrolizumab for recurrent or metastatic disease  – –  CMC path in place to support delivery of product for Phase 2 study as well as future framework to support potential pivotal trials – GERMANTOWN, Md. , May 31, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application to initiate a Phase 2 study of the first-in-class PRGN-2009 Off-the-Shelf (OTS) AdenoVerse ™ immunotherapy in combination with pembrolizumab in patients with recurrent or metastatic cervical cancer.

Precigen Receives FDA Clearance of IND to Initiate Phase 2 Study of PRGN-2009 Off-the-Shelf AdenoVerse Immunotherapy in Combination with Pembrolizumab to Treat Patients with Recurrent or Metastatic Cervical Cancer

Bionano Genomics

23andMe

High-risk penny stocks have long tempted investors with the potential for significant returns. However, it is crucial to acknowledge the inherent risks associated with these speculative investments.

Hero or Zero? 3 High-Risk Penny Stocks to Make You Rich

Precigen, Inc. (NASDAQ:PGEN ) Q1 2023 Earnings Conference Call May 10, 2023 8:00 AM ET Company Participants Steve Harasym - Vice President, Investor Relations Helen Sabzevari - President & Chief Executive Officer Harry Thomasian - Chief Financial Officer Conference Call Participants Jason Butler - JMP Securities Jennifer Kim - Cantor Fitzgerald Carolina Ibanez Ventoso - Stifel Arthur He - H.C. Wainwright Operator Good morning, and welcome to the Precision First Quarter 2023 Financial Results and Business Update Call.

Precigen, Inc. (PGEN) Q1 2023 Earnings Call Transcript

–   Positive Phase 1 clinical data presented for PRGN-2012 AdenoVerse ™  immunotherapy in RRP demonstrated favorable safety profile and significant reduction in surgeries with 50% of the patients in Complete Response following treatment with PRGN-2012 – –  Enrollment completed in the Phase 2 study of PRGN-2012 in RRP – –  First patient dosed in Phase 1/1b dose escalation/dose expansion study of PRGN-3007, a next generation UltraCAR-T® incorporating PD-1 checkpoint inhibition, in advanced ROR1+ hematological and solid tumors – –  Regained exclusive rights to validated CAR-T targets, CD19 and BCMA, to enable unencumbered development and commercialization of UltraCAR-T® – –  Latest clinical advancements for PRGN-3005 UltraCAR-T® and PRGN-2009 off-the-shelf AdenoVerse ™ immunotherapy to be presented at the 2023 ASCO annual meeting in June – –  Significantly strengthened balance sheet, raising $72.8 million, net of offering costs via a public offering of common stock – –  Retired an additional $29.5 million of outstanding convertible notes, leaving $13.8 million maturing on July 1, 2023 , which will be retired using the Company's restricted cash balance – –  Cash, cash equivalents, short-term and long-term investments and restricted cash totaled $125.4 million as of March 31, 2023 – GERMANTOWN, Md. , May 10, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced first quarter 2023 financial results and business updates.

Precigen Reports First Quarter 2023 Financial Results and Business Updates

Cue Biopharma

Sana Biotechnology

Ardelyx

Atossa Genetics

Bioline RX

Corvus Pharmaceuticals

Most of the biggest biotech stocks on the market started off as unknown penny stocks. Look at Axsome Therapeutics (NASDAQ: AXSM ), for example.

7 High-Potential Penny Stocks in the Biotech Sector

GERMANTOWN, Md. , May 3, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will release first quarter 2023 financial results on Wednesday, May 10, 2023.

Precigen to Announce First Quarter 2023 Financial Results on May 10th

GERMANTOWN, Md. , April 26, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced clinical data from the Phase 1 dose escalation study of PRGN-3005 UltraCAR-T in patients with advanced, recurrent platinum resistant ovarian cancer, and the Phase I study of PRGN-2009 AdenoVerse immunotherapy alone or in combination with an anti-PDL1/TGF-Beta trap checkpoint inhibitor in patients with HPV-associated cancers will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place from June 2-6, 2023 at McCormick Place in Chicago, Illinois.

Precigen to Present Latest Clinical Advancements for PRGN-3005 UltraCAR-T® and PRGN-2009 Off-the-Shelf AdenoVerse™ Immunotherapy at the 2023 ASCO Annual Meeting

American Assets

AbbVie

Byline Bancorp

Coastal Financial Corp

Clear Channel Outdoor Holdings

Compass Minerals

Enovix Corporation

Heartland Express

iHeartMedia

JELD-WEN Hld

Mineralys Therapeutics Inc

OPKO Health

PacWest Bancorp

Paramount Group

Purple Innovation

B. Riley Financial

Cassava Sciences Inc

Summit Therapeutics

SPDR S&P 500 ETF Trust

Triumph Financial Inc

LendingTree

Vera Therapeutics

Strong Small-Cap Insider Buys: Q1 2023

Ascent Solar Technologies Inc

Chanson International Holding

Presto Automation Inc

Sunlight Financial Holdings

Penny stocks to watch today. The post 5 Penny Stocks To Watch Today; Is It Time To Buy?

5 Penny Stocks To Watch Today; Is It Time To Buy?

Intellia Therapeutics

Vertex Pharmaceuticals

Many investors look for growth opportunities wherever they can find them. If that describes you, then there are some high-growth biotech stocks that could present an opportunity.

3 High-Growth Biotech Stocks Poised for Success in 2023

GERMANTOWN, Md., April 17, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today presents preclinical data for the next generation UltraCAR-T platform utilizing MSLN CAR from Precigen's library of non-viral plasmids at the American Association for Cancer Research (AACR) Annual Meeting 2023

Precigen Presents Preclinical Data for the Next Generation Mesothelin UltraCAR-T® with Intrinsic PD-1 Blockade at the AACR Annual Meeting 2023

–  Precigen amends exclusive license agreement with Alaunos to bolster portfolio and broaden strategic opportunities  – –  The Company also regains exclusive rights to IL-12 gene therapy, including application through the AdenoVerse™ platform –  Agreement eliminates all future royalties to Alaunos – –  Precigen to host business and clinical update call on Tuesday, April 4, 2023 at 8:30 AM ET – GERMANTOWN, Md. , April 3, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the amendment of its exclusive license agreement with Alaunos Therapeutics, Inc. (Alaunos).

Precigen Regains Exclusive Rights to Proven CAR-T Targets, CD19 and BCMA, to Enable Unencumbered Development and Commercialization of UltraCAR-T®

– Milestone represents the first patient dosed with the next generation UltraCAR-T, incorporating PD-1 checkpoint inhibition in addition to three effector genes – – Proprietary technology for checkpoint blockade intrinsic to UltraCAR-T cells avoids the need for combination with a systemic checkpoint inhibitor, potentially limiting cost and systemic toxicity – GERMANTOWN, Md. , March 29, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the first patient has been dosed in the Phase 1/1b dose escalation/dose expansion study (clinical trial identifier: NCT05694364) of PRGN-3007 in advanced ROR1-positive (ROR1+) hematological and solid tumors.

Precigen Announces Further Advancement of UltraCAR-T® Platform with First Patient Dosed in Phase 1/1b Dose Escalation/Dose Expansion Study of PRGN-3007 in Advanced ROR1+ Hematological and Solid Tumors

GERMANTOWN, Md. , March 28, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari, PhD, President and CEO of Precigen, will participate in a virtual fireside chat on April 4, 2023 from 10:45 AM to 11:15 AM ET at Cantor's "The Future of Oncology" Virtual Symposium.

Precigen to Participate in a Virtual Fireside Chat at Cantor's "The Future of Oncology" Virtual Symposium

Zai Lab Ltd.

When biotechs launch drugs or report on clinical trials, their shares can jump in a big way. Precigen's technology could make it a leader in low-cost immunotherapies.

2 Unmatched Stocks Wall Street Thinks Will Soar 152% or More in the Next 2 Years

Asana

Charles Schwab

Shopify

Solar Capital

SoFi Technologies

Twilio

The Executive Vice President of the Dish Network (NASDAQ: DISH ) is Jim DeFranco. He also happens to be a co-founder of the satellite TV provider.

Founders at These 7 Companies Are Loading Up on Their Stock. Should You?

Precigen, Inc. (PGEN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Here's Why Precigen, Inc. (PGEN) Is a Great 'Buy the Bottom' Stock Now

Jasper Therapeutics

Quotient Technology

Tcr2 Therapeutics

thredUP

Penny stocks to buy according to analysts in 2023 The post 5 Penny Stocks To Buy According To Analysts, Targets Up To 952% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Penny Stocks To Buy According To Analysts, Targets Up To 952%

–  Achieved significant clinical progress for UltraCAR-T ® and AdenoVerse ™  investigational therapeutics in 2022 – –  Presented positive clinical data for PRGN-2012 AdenoVerse immunotherapy in recurrent respiratory papillomatosis (RRP) showing favorable safety profile and significant reduction in surgeries with 50% of the patients in Complete Response following treatment with PRGN-2012 – –  Presented positive clinical data for PRGN-3006 UltraCAR-T in relapsed or refractory (r/r) acute myeloid leukemia (AML) showing a favorable safety profile, 27% objective response rate (ORR) and reduction in AML blasts in the majority of patients following treatment with PRGN-3006 – –  Significantly strengthened balance sheet via successful divesture of non-health subsidiary in the third quarter, retirement of the majority of the Company's $200 million outstanding convertible notes, and raising approximately $73 million (after deducting underwriting discounts, fees and other underwriting expenses) via a public offering of common stock – –  Cash, cash equivalents, short-term investments and restricted cash totaled $99.7 million as of December 31, 2022 – GERMANTOWN, Md. , March 6, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced fourth quarter and full year 2022 financial results.

Precigen Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates

Altimmune

Foghorn Therapeutics

Concerns about a tough financing environment weighed on clinical-stage biotech stocks this week.

Why Altimmune, Foghorn Therapeutics, and Precigen Shares Crashed This Week

Advanced Emissions Solutions

Express

Penny stocks to buy according to insider trades this quarter. The post 3 Penny Stocks To Buy According To Insider Bets Up To $25 Million appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Penny Stocks To Buy According To Insider Bets Up To $25 Million

GERMANTOWN, Md. , Jan. 27, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN) announced today the closing of its previously announced underwritten public offering of common stock.

Precigen Announces Closing of Public Offering of Common Stock

Precigen, Inc. (PGEN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Precigen, Inc. (PGEN) Moves to Buy: Rationale Behind the Upgrade

GERMANTOWN, Md. , Jan. 24, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN) today announced the pricing of an underwritten public offering of 42,857,143 shares of its common stock at a public offering price of $1.75 per share.

Precigen Announces Pricing of $75.0 Million Public Offering of Common Stock

GERMANTOWN, Md. , Jan. 24, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN) today announced it has commenced an underwritten public offering of $75.0 million of its common stock.

Precigen Announces Proposed $75.0 Million Public Offering of Common Stock

News for Precigen Stock (PGEN)